There is evidence that mouse models of Huntington’s disease (HD) express lower levels of the glial glutamate transporter GLT1 in the striatum, and that ceftriaxone (a drug that promotes GLT1 expression) ameliorates the motor deficits in these mice. Here, SLC1A2 is linked to Huntington disease.